tarlatamab + YL201 + atezolizumab

This product is an investigational **combination therapy** consisting of three agents: - **Tarlatamab**: a bispecific T-cell engager immunotherapy that targets *delta-like ligand 3 (DLL3)* on tumor cells and *CD3* on T cells, facilitating T-cell-mediated lysis of DLL3-expressing cancer cells. - **YL201**: a B7-H3–targeting antibody-drug conjugate (ADC) that delivers a tumor-activated cytotoxic payload (TMALIN linker-payload) specifically to B7-H3 expressing tumor cells. - **Atezolizumab**: a monoclonal antibody that inhibits *programmed death ligand 1 (PD-L1)*, enhancing immune response against cancer cells. The combination is being developed and investigated primarily for **extensive-stage small cell lung cancer (ES-SCLC)**, with the intention to improve efficacy through synergistic anti-tumor immune mechanisms. The regimen is in early clinical development (Phase I trials) for relapsed/refractory ES-SCLC and is evaluated for safety, tolerability, and preliminary efficacy[1][2][3][6][9].

Brand names

Imdelltra (tarlatamab)Tecentriq (atezolizumab)

Other names

anti–PD-L1 antibody (for atezolizumab)